Related Experiment Video
Updated: Jun 26, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Different cervical cancer screening approaches in a Chinese multicentre study
1International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France.
British Journal of Cancer
|January 8, 2009
Summary
Liquid-based cytology (LBC) and Hybrid Capture 2 (HC2) testing demonstrated high accuracy for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Visual inspection with acetic acid (VIA) showed lower sensitivity, especially in older women.
Area of Science:
- Gynecology
- Oncology
- Public Health
Background:
- Cervical cancer screening is crucial for early detection and prevention.
- Evaluating alternative screening methods is essential for improving effectiveness and accessibility.
- Traditional methods like Visual Inspection with Acetic Acid (VIA) have limitations.
Purpose of the Study:
- To compare the performance of digital colposcopy, liquid-based cytology (LBC), and Hybrid Capture 2 (HC2) for cervical cancer screening.
- To assess the sensitivity and specificity of these methods in detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+).
Main Methods:
- A study involving 2562 women aged 15-59 in China.
- Methods evaluated included digital colposcopy, VIA, LBC, and HC2 testing.
- Histological confirmation of CIN2+ was used as the gold standard, with adjustments for verification bias.
Main Results:
- LBC (≥ASCUS) sensitivity: 87%, HC2 sensitivity: 90%, LBC+HC2 sensitivity: 96%.
- VIA sensitivity: 37% (lower in women ≥40 years: 12%). Digital colposcopy sensitivity: 54%.
- Specificity ranged from 77% (LBC+HC2) to 94% (LBC with HC2 triage).
Conclusions:
- LBC, HC2, and their combinations are effective screening methods for CIN2+.
- VIA demonstrated significantly lower sensitivity, particularly in older women.
- Digital colposcopy showed moderate performance, outperforming VIA but missing nearly half of CIN2+ cases.